Geron Corp

Geron’s restructuring and IMerge data show telomerase inhibitor imetelstat may turn side‑effect cytopenias into on‑target cancer benefits.

Geron Corp’s telomerase‑inhibitor imetelstat targets myeloid cancers—discover the company’s biotech focus, market performance, and future prospects.

Geron Corporation has announced a series of executive leadership changes aimed at strengthening its commercial focus, including the departure of its current CEO and the appointment of new leaders in key areas such as commercial and scientific strate…